Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$17.38 USD
-0.33 (-1.86%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $17.38 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ARQT 17.38 -0.33(-1.86%)
Will ARQT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARQT
Are Medical Stocks Lagging AxoGen (AXGN) This Year?
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
Other News for ARQT
ARQT forms Three Weeks Tight on September 19
The technical outlook for ARQT is unchanged after it rises 3.33% on September 18
ARQT's price rises by 1.0% on September 17, though its technical setup remains stable.
Is ARQT primed for upward momentum? Non-ADX 1,2,3,4 Bullish shows up after rising 0.24%
Arcutis Biotherapeutics (ARQT) Unveils Positive Data on Zoryve Foam at Dermatology Congress